TinyGemsBreaks Archive - Page 108 of 137

ThursdayNov 03, 2022 10:00 am

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Distinctive in Highly Competitive Online Gambling Space

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, white labels its industry-leading GM-AG System that can be custom-built from 10,000+ game options for its roughly 650 clients serving about 6.8 million end users. “The online gambling space is highly competitive, leading to most of the world’s biggest operators burning through tons of cash for marketing in a bid to try and attract (and keep) customers. That’s cash that comes straight off the bottom line, explaining why many struggle to achieve profitability. That’s certainly not the case for GMGI, which continues to experience…

WednesdayNov 02, 2022 2:15 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Eyes Steady Growth, Traction in Distinctive Solutions

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has grown its operations with numerous improvements to its cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. In addition, Fr8Tech is constantly exploring new ways to create value for its clients, streamline the region’s cross-border shipping process, and carry that over into respective domestic markets. Its efforts to date have yielded six distinctive solutions in its product suite: Fr8App, Fr8Radar, Fr8TMS, Fr8FMS, Fr8Data, and Fr8Fleet. A recent article reads, “The company’s focus on exploring new areas for revenue and value creation allowed for a 45% year-over-year (‘YOY’) revenue growth for…

WednesdayNov 02, 2022 11:52 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing…

WednesdayNov 02, 2022 10:33 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Eliminates Some $13M in Debt

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has eliminated $13 million in company debt, resulting in a reduction of overall indebtedness from more than $30 million last year to less than $10 million currently. The company has been working to strengthen its financial balance sheet; it also recently eliminated some $13 million of company debt associated with Esousa Holdings LLC. According to the announcement, MULN believes this debt conversion will save more than $3.5 million in interest expenses. With less than $10 million left of outstanding indebtedness, Mullen is maintaining its strong financial health. “It’s been a…

TuesdayNov 01, 2022 1:35 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance and data solutions for healthcare facilities; two hotels — one in Tennessee and one in Washington state; a sports complex in New York; and a multifamily housing complex in Pennsylvania. The contracts call for Knightscope ASRs to patrol and provide surveillance for everything from parking lots…

TuesdayNov 01, 2022 1:23 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

TuesdayNov 01, 2022 12:57 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

MondayOct 31, 2022 1:52 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

MondayOct 31, 2022 1:38 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Secures LOI for up to $100M to Help Fund next Stage of Growth

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance lidar solutions, has rapidly emerged as a leader amongst its peers – deploying its unique capabilities across a host of different environments, ranging from traffic systems in Cape Town, South Africa, to airport terminal monitoring in the U.S. “Cepton’s long-term automotive Tier 1 partner, Koito Manufacturing Co. Ltd., recently revealed that it had provided Cepton with a letter of intent representing an investment of up to $100 million to help fund Cepton’s next stage of growth as it seeks to scale its lidar solutions for mass deployment,” a recent…

MondayOct 31, 2022 10:17 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Shares Responses from Participants of Its Strikingly Different FIVE EV Crossover Tour

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is seeing an overwhelmingly positive response to its Strikingly Different FIVE EV Crossover tour. Tour participants, including potential buyers and Mullen investors, who reserve a spot on the tour are enjoying the opportunity to ride the Mullen EV Crossover and personally interact with Mullen’s updated infotainment system, which features PERSONA, Mullen’s proprietary Personal Vehicle Assistant technology. PERSONA uses the latest facial recognition technology, which enables the vehicle to provide a highly personalized experience to every driver of the Mullen FIVE. The tour kicked off in Pasadena, California, last week, and has…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks